Healthcare Services

Global Edema Clinical Trials Market Anticipated To Grow To $1.85 Billion By 2030 At 8.5% CAGR

May 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Size Of The Edema Clinical Trials Market Progress Through 2030?

The edema clinical trials market has shown strong expansion in recent years. This market is projected to expand from $1.23 billion in 2025 to $1.34 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. Factors contributing to its historical growth include the rising prevalence of cardiovascular and renal disorders, the development of clinical research infrastructure, increased pharmaceutical R&D investments, a surge in investigator-led trials, and advancements in clinical trial management systems.

The edema clinical trials market is projected to experience robust expansion over the coming years. Its valuation is set to reach $1.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period is primarily driven by factors such as a heightened demand for specialized edema treatments, the increasing adoption of decentralized clinical trial methodologies, the broadening scope of precision medicine strategies, the enhanced integration of digital tools for data collection, and increased regulatory backing for novel trial structures. Key trends anticipated during this period encompass the growing application of AI in patient recruitment, a rise in the implementation of adaptive trial designs, an intensified focus on endpoints based on biomarkers, the broadening of multi-center global trials, and a strengthened commitment to incorporating real-world evidence.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28211&type=smp

Which Major Factors Are Contributing To The Development Of The Edema Clinical Trials Market?

The rising occurrence of lifestyle-associated illnesses is anticipated to fuel the expansion of the edema clinical trials market in the future. These diseases are conditions resulting from everyday habits and decisions, such as a sedentary lifestyle, poor dietary choices, and substance consumption. The prevalence of lifestyle diseases is escalating, driven by detrimental eating patterns, where the common intake of processed and calorie-rich items leads to issues like obesity, diabetes, and heart-related complications. Edema clinical trials play a crucial role in aiding lifestyle-related diseases through the creation and evaluation of therapies targeting fluid accumulation associated with obesity, diabetes, and cardiovascular conditions. For example, data from March 2024, provided by the Office for Health Improvement & Disparities, a UK government body, indicated that from March 2022 to March 2023, the proportion of individuals with type 1 diabetes undergoing all eight recommended care processes saw a rise of 22%. Similarly, for type 2 diabetes, this figure increased by 21%, and the proportion reaching target HbA1c levels climbed to 37.9%, marking the highest value ever recorded by the National Diabetes Audit (NDA). Consequently, the growing occurrence of lifestyle-related diseases is fueling the expansion of the edema clinical trials market.

What Key Segment Areas Are Included In The Edema Clinical Trials Market Assessment?

The edema clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Type: Peripheral Edema, Pulmonary Edema, Cerebral Edema, Nephrotic Syndrome Edema

3) By Study Design: Interventional, Observational, Expanded Access

4) By Participant: Pediatrics, Adults, Geriatrics

5) By End User: Pharmaceutical Companies, Research Institutions, Contract Research Organizations (CROs), Academic Research Centers

Subsegments:

1) By Phase I: Single Ascending Dose, Multiple Ascending Dose

2) By Phase II: Proof of Concept, Phase IIb Dose Optimization

3) By Phase III: Pivotal Efficacy Trials, Comparative Trials

4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies

Which Trends Are Affecting The Edema Clinical Trials Market Framework?

Leading companies in the edema clinical trials market are focusing on creating advanced solutions, such as refillable ocular implants, to boost treatment effectiveness and patient adherence in managing chronic edema-related eye conditions. A refillable ocular implant is a medical device implanted in the eye, designed to continuously administer medication over an extended period. It also allows for regular drug replenishment without requiring the implant’s removal or replacement, thus ensuring sustained therapy for persistent eye conditions like macular edema. For instance, in February 2025, Roche Holding AG, a Switzerland-based pharmaceutical company, received FDA approval for Susvimo. This makes it the first and only continuous delivery treatment available for diabetic macular edema (DME) and diabetic retinopathy (DR), both significant causes of diabetes-related blindness, providing an alternative to frequent eye injections with considerably fewer annual treatments. This innovative approval represents a major leap forward in ophthalmic care, as Susvimo’s implantable delivery system helps enhance patient compliance and lessen the treatment burden, potentially leading to better long-term outcomes for individuals living with these chronic eye conditions.

Who Are The Major Companies Operating In The Edema Clinical Trials Market?

Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG

Access The Complete Edema Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/edema-clinical-trials-global-market-report

What Is The Largest Regional Market In The Edema Clinical Trials Market?

North America was the largest region in the edema clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the edema clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Edema Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=28211&type=smp

Browse Through More Reports Similar to the Global Edema Clinical Trials Market 2026, By The Business Research Company

Atopic Dermatitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Eye Melanoma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Seborrheic Dermatitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/seborrheic-dermatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795